What This PTC Therapeutics Insider Sale Means as Product Revenue Hit $226 Million
This insider maintains 63,198 shares across direct and indirect accounts while holding 45,036 derivative securities.
Overview
Neil Gregory Almstead, the chief technical ops officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), sold 2,464 shares of common stock on July 9, 2026, at $90.25 per share, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($90.25); post-transaction value based on July 09, 2026 market close ($89.55).
Details
PTC Therapeutics is a biopharmaceutical enterprise with a market capitalization of $7 billion. The company has achieved TTM revenue of $827.1 million, demonstrating meaningful commercial traction in the rare disease therapeutics market. PTC's competitive differentiation lies in its specialized expertise in rare genetic diseases, coupled with a diversified pipeline spanning early-stage research through late-stage clinical development, positioning the company to capture significant value as pipeline candidates advance toward regulatory approval and commercialization.
Source
Originally published at www.fool.com.